Study compares switching atopic dermatitis drugs versus staying on upadacitinib

A clinical trial examined whether patients with moderate-to-severe atopic dermatitis could safely switch from dupilumab to upadacitinib, or if continuous upadacitinib treatment worked better. The findings could shape treatment protocols and drug-switching strategies for dermatologists, affecting which therapies insurers prioritize and how pharmaceutical companies position competing biologics and JAK inhibitors.

Originaltitel: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)